ArriVent BioPharma, Inc.
ArriVent BioPharma, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Next quarterly earnings (projected) on November 11, 2026, a projected date rather than a confirmed one. There are 4 upcoming events on record.
Cash runway is approximately 26.7 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
| Date | Event | Type | Phase |
|---|---|---|---|
| November 11, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| August 15, 2027 | Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer. | Trial Milestone | Phase 1 |
| March 15, 2028 | A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors | Trial Milestone | Phase 1 |
| February 15, 2029 | Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations | Trial Milestone | Phase 3 |
Track AVBP alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open AVBP in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.